Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., Nov. 1, 2024 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 10,500 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of October 31, 2024 (the “Grant Date”) pursuant to the Company’s 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee’s continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates. In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a “change in control event,” the employee’s employment is terminated for “good reason” by the employee or terminated without “cause” by Karyopharm (as such terms are defined in the applicable RSU agreement).

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm’s lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­ U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302290086.html

SOURCE Karyopharm Therapeutics Inc.

Staff

Recent Posts

Pioneering Scientist David Deamer to receive ABRF Award for Outstanding Contributions to Biomolecular Technologies

 LEXINGTON, Ky. , Nov. 2, 2024 /PRNewswire/ -- The Association of Biomolecular Resource Facilities (ABRF) is…

1 day ago

Optimal Breathing Holds its Annual Black Friday Sale

Turbo Oxygen EWOt System with 900 Liter Oxygen Reservoir Bag and Patented Mega-Flow Mask with…

1 day ago

Nihon Kohden Introduces First-Ever ATO-Certified Ventilators

IRVINE, Calif.--(BUSINESS WIRE)--#RespiratoryCare--Nihon Kohden, a global leader in medical technology, today announced the introduction of…

2 days ago

2025 Medicare Physician Fee Schedule Final Rule Includes Two Major Wins for Therapy Providers

APTA advocacy leads to impactful policy wins that will reduce administrative burden, improve access, and…

2 days ago

Gestalt and Paige Partner to Enhance Digital Pathology Workflows with Integration of Advanced AI Algorithms

SPOKANE, Wash. and NEW YORK, Nov. 1, 2024 /PRNewswire/ -- Gestalt, a leader in digital pathology…

2 days ago

Wasatch BioLabs and Oxford Nanopore Team Up to Accelerate Methylation Sequencing Towards Clinical Use

SALT LAKE CITY and OXFORD, United Kingdom, Nov. 1, 2024 /PRNewswire/ -- Wasatch Biolabs (WBL),…

2 days ago